The clearance is the first for an oral peptide that blocks IL-23, the target of popular medicines like Skyrizi and Tremfya. J ...

J&J wins FDA nod for Icotyde, a once-daily oral psoriasis pill, boosting its new drugs portfolio and challenging injectable treatments in a key market.

AbbVie (ABBV) stock dips as BNP warns J&J’s (JNJ) newly FDA-approved plaque psoriasis pill, Icotyde, may challenge its blockbuster drug, Skyrizi. Read more here.

More than 80% of those treated with TREMFYA® were in clinical remission and more than 50% were in endoscopic remission at Week 140 of the QUASAR long-term extension ...

The first-of-its-kind oral pill could replace injectable medications for some patients with psoriasis, dermatologists say.

CMO, director of clinical research at Frontier Dermatology in Mill Creek, Washington, discussed studies presented at Maui Derm 2026 that examined high-impact psoriasis sites.

In recent months, Johnson & Johnson has massively upped its spending on television advertisements for immunology heavyweight Tremfya, with the brand topping the list of the biggest TV drug ad spenders ...

QUASAR long‑term extension results highlight durable clinical and endoscopic outcomes Johnson & Johnson has reported new long‑term results from the QUASAR long‑term extension study, showing that ...

While Johnson & Johnson retains the top revenue rank across the major pharma companies, Eli Lilly last year established ...

AbbVie Inc. (NYSE:ABBV) is among the 7 Most Promising Psychedelic Stocks According to Hedge Funds. AbbVie Inc. (NYSE:ABBV) tops our list for being one of the most promising stocks. TheFly reported on ...